A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer (NCT05154487)
Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers
🩺 Plain-English Summary (8th-Grade Level)
This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate (ORR). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- City of Hope — Duarte, California
- Mount Sinai Medical Center — Miami Beach, Florida
- AdventHealth Gynecologic Oncology — Orlando, Florida
- Tampa General Hospital — Tampa, Florida
- Moffit Cancer Center at International Plaza — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
- Moffit Cancer Center at Wesley Chapel — Wesley Chapel, Florida
- Endeavor Health — Evanston, Illinois
- Endeavor Health Clinical Operations, Glenbrook Hospital — Glenview, Illinois
- Endeavor Health Clinical Operations, Highland Park Hospital — Highland Park, Illinois
- Ascension St. Vincent — Indianapolis, Indiana
- Norton Cancer Institute — Louisville, Kentucky
- Johns Hopkins Medicine — Baltimore, Maryland
- Northwell Health Cancer Institute — Lake Success, New York
- QCC- Northwell Health Physicians Partners Medical — Rego Park, New York
- Kettering Health Cancer Center — Kettering, Ohio
- Oklahoma Cancer Specialists and Research Institute, LLC — Tulsa, Oklahoma
- Legacy Good Samaritan Medical Center — Portland, Oregon
- Legacy Meridian Park Medical Center — Tualatin, Oregon
- Legacy Salmon Creek Medical Center — Vancouver, Washington
- University of Wisconsin Clinical Science Center — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Endometroid Endometrial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.